Spyre Therapeutics Shares Drop After Mixed Phase 2 Trial Results
Spyre Therapeutics (SYRE) experienced a roughly 12% decline in after-hours trading following the release of mixed phase 2 trial results for its rheumatoid arthritis candidate, SPY072. The low dose met the primary endpoint related to change from baseline in DAS28-CRP but failed on other key measures. The disappointing data raised concerns about the drug's efficacy and potential commercial viability, leading investors to reassess their positions. Market reaction was swift as after-hours trading reflected reduced confidence in Spyre’s pipeline progress for this indication.
Tickers: $SYRE